Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2020-05-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding specific board meeting matters, including approval of a subsidiary loan guarantee and an accounting estimate change. It references compliance with regulatory guidelines and company governance rules. The document is short (1143 characters) and does not contain financial statements or detailed financial data. It is not a full annual or interim report, nor an earnings release. It is not a certification letter but an opinion related to board meeting decisions. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or management decisions.
2020-05-19 Chinese
关于召开2020年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2020 third extraordinary general meeting of shareholders for Zhuhai Sailong Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, agenda items, and proxy authorization forms. There is no financial data, earnings information, or report content. The document serves as an announcement to shareholders about the meeting and voting process rather than the meeting minutes or voting results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-05-19 Chinese
关于会计估计变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding a change in accounting estimates related to the depreciation period of fixed assets (buildings). It details the board and supervisory committee meetings where the change was approved, the rationale for the change, and the impact on financial results. The document is relatively short (1937 characters) and does not contain full financial statements or comprehensive financial data. It is a formal disclosure about an accounting policy change rather than a full audit report or annual/interim report. This type of announcement fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about accounting estimate changes without the full audit or financial report content.
2020-05-19 Chinese
关于为子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhuhai Sailong Pharmaceutical Co., Ltd. regarding the provision of guarantees for its subsidiary's borrowings. It details the board meeting resolutions, the guarantee agreements, the purpose and impact of the guarantees, and the approval process including independent directors' opinions. The document does not contain financial statements or detailed financial performance data but is a formal disclosure of a corporate action related to financing guarantees. It is not a full financial report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits best with a Capital/Financing Update (CAP) as it concerns financing activities and guarantees provided by the company for its subsidiary's borrowings.
2020-05-19 Chinese
关于子公司拟参与竞拍土地使用权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding its subsidiary's intention to participate in a public auction for land use rights. It details the background, transaction parties, land specifics, and potential impact on the company. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a formal disclosure about a capital investment activity related to land acquisition, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and is a direct announcement, not a report publication or certification. Therefore, the appropriate classification is CAP with high confidence.
2020-05-19 Chinese
第二届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Zhuhai Sailong Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items discussed, voting results, and references to related announcements on a public information website. The content focuses on board decisions such as approval of subsidiary land bidding, loan guarantees, accounting estimate changes, and calling a shareholders meeting. There are no financial statements or detailed financial performance data presented. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting results declaration but rather a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (2178 characters), and it is a direct announcement of board meeting resolutions, not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2020-05-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.